Street:Daechi-Dong 890-47 Miso Bldg. 10th Fl. Gangnam-Gu, Seoul 135-280 Korea
MaxCard:
About us
Welcome To Our Site!
Enzychem Lifesciences is a venture corporation that was founded on the most advanced life sciences and technologies of precision chemistry in July 1999. With its central research center located in KAIST in Daejon and its GMP manufacturing plant in Jecheon, it has since been developing and producing APIs and global new drugs as the leader of the field.
Enzychem is an innovative enterprise marketing APIs both domestically and overseas. It has acquired certification as a domestic enterprise of new technologies (the Korean Mark of New Technology, the Certificate of New
Health Technology, Innobiz, a Model Corporation of Innovative Technologies) and developed drugs to treat sepsis, cancers,
and autoimmune disorders that uses EC18 (a substance naturally derived from deer antlers). It also owns dozens of intellectual properties with regard to the syntheses of 1st generic ingredient drugs and produces APIs surpassing EU GMP quality standards thanks to its state-of-the-art GMP facilities for synthesis. In addition, after its first GMP plant (specializing in the production of cephalosporin), it completed its second GMP plant (specializing the manufacture of non-cephalosporin) in October 2012. It is now pushing for the commercialization of not only cephalosporin but also non-cephalosporin functional health products that enhance functions of immunity.
Enzychem is a life sciences enterprise in which institutional investors, including Korea Development Bank (KDB), Korea Development Bank Capital (KDBC), and Hanwha Investment (HWVC), have invested. Based on its solid financial foundation,
it has achieved growth rates of over 30% annually. Also based on its sustained R&D and business growth, Enzychem aims
at a Kosdaq IPO in2014 and the development of new drugs to treat cancers and immune disorders in 2016.
Korea
